Lead Pharma Competitors and Similar CompaniesClear all

Lead Pharma's competitors and similar companies include Rakuten Medical, OncoArendi Therapeutics, Karo Healthcare and Oscotec.

	Lead Pharma Lead Pharma is a company that discovers, develops, and commercializes therapeutics against cancer and autoimmune diseases.	Rakuten Medical Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies.	OncoArendi Therapeutics OncoArendi Therapeutics is a biotech company focused on discovery and development of small molecule drug candidates.	Karo Healthcare Karo Healthcare is a healthcare company, which develops and markets products for pharmacies and the health care sectors.	Oscotec Oscotec is a clinical stage drug discovery and development company.
Founding Date	Founding Date 2007	Founding Date 2013	Founding Date 2012	Founding Date 1987	Founding Date 1998
Type	Type Private	Type Private	Type Private	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma therapy	Tags Healthcare biotech drug development oncology pharma therapy	Tags Healthcare biotech drug development oncology pharma therapy	Tags Healthcare biotech drug development oncology pharma therapy	Tags Healthcare biotech drug development oncology pharma therapy
Locations	Locations Oss, NL HQ Oss, NL	Locations San Diego, US HQ Setagaya City, JP Amsterdam, NL Ecublens, CH Taipei, TW Taipei, TW San Mateo, US	Locations Warszawa, PL HQ Łódź, PL	Locations Stockholm, SE HQ Stockholm, SE	Locations Seongnam-si, KR HQ
Employees	Employees 363% decrease	Employees 1241% increase	Employees 839% increase	Employees 225	Employees 50
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) kr3b (FY, 2021)	Revenue (est.) ₩99.8b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods kr1.3b (FY, 2021)	Cost of goods ₩438.8m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit kr1.7b (FY, 2021)	Gross profit ₩100b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income (kr17m) (FY, 2021)	Net income ₩54.4b (FY, 2025)